BR112012006630A2 - derivados em indol como moduladores dos canais de cálcio ativados para liberação de cálcio (crac) - Google Patents
derivados em indol como moduladores dos canais de cálcio ativados para liberação de cálcio (crac)Info
- Publication number
- BR112012006630A2 BR112012006630A2 BR112012006630A BR112012006630A BR112012006630A2 BR 112012006630 A2 BR112012006630 A2 BR 112012006630A2 BR 112012006630 A BR112012006630 A BR 112012006630A BR 112012006630 A BR112012006630 A BR 112012006630A BR 112012006630 A2 BR112012006630 A2 BR 112012006630A2
- Authority
- BR
- Brazil
- Prior art keywords
- calcium channel
- crac
- indole derivatives
- modulators
- activated
- Prior art date
Links
- 108090000312 Calcium Channels Proteins 0.000 title 2
- 102000003922 Calcium Channels Human genes 0.000 title 2
- 229940054051 antipsychotic indole derivative Drugs 0.000 title 1
- 150000001669 calcium Chemical class 0.000 title 1
- 150000002475 indoles Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24552109P | 2009-09-24 | 2009-09-24 | |
| US37806210P | 2010-08-30 | 2010-08-30 | |
| PCT/EP2010/063838 WO2011036130A1 (en) | 2009-09-24 | 2010-09-21 | Indole derivatives as crac modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012006630A2 true BR112012006630A2 (pt) | 2016-05-03 |
Family
ID=43432437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012006630A BR112012006630A2 (pt) | 2009-09-24 | 2010-09-21 | derivados em indol como moduladores dos canais de cálcio ativados para liberação de cálcio (crac) |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110071150A1 (pt) |
| EP (1) | EP2480529A1 (pt) |
| JP (2) | JP2013505913A (pt) |
| KR (1) | KR20120068947A (pt) |
| CN (1) | CN102574788A (pt) |
| AR (1) | AR078408A1 (pt) |
| BR (1) | BR112012006630A2 (pt) |
| CA (1) | CA2771026A1 (pt) |
| MX (1) | MX2012003539A (pt) |
| RU (1) | RU2012116207A (pt) |
| TW (1) | TW201121952A (pt) |
| WO (1) | WO2011036130A1 (pt) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI423962B (zh) * | 2009-10-07 | 2014-01-21 | Lg Life Sciences Ltd | 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物 |
| JP2013530180A (ja) | 2010-06-16 | 2013-07-25 | パーデュー、ファーマ、リミテッド、パートナーシップ | アリール置換インドールおよびその使用 |
| US20130109720A1 (en) * | 2011-11-01 | 2013-05-02 | Hoffmann-La Roche Inc. | Indole inhibitors of crac |
| US20130158066A1 (en) * | 2011-12-20 | 2013-06-20 | Hoffmann-La Roche Inc. | 4-azaindole inhibitors of crac |
| WO2013092467A1 (en) * | 2011-12-20 | 2013-06-27 | F. Hoffmann-La Roche Ag | 7-azaindole inhibitors of crac |
| WO2013092444A1 (en) * | 2011-12-20 | 2013-06-27 | F. Hoffmann-La Roche Ag | Diazaindole inhibitors of crac |
| JP2015534957A (ja) * | 2012-10-17 | 2015-12-07 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｔｒｐチャネル拮抗薬としての６−アミノインドール誘導体 |
| JP5758864B2 (ja) | 2012-11-08 | 2015-08-05 | ファナック株式会社 | ブレーキの状態を解放状態から締結状態に迅速に変更するブレーキ駆動制御装置 |
| EP2738172A1 (en) | 2012-11-28 | 2014-06-04 | Almirall, S.A. | New bicyclic compounds as crac channel modulators |
| US9650375B2 (en) * | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
| EP2848615A1 (en) | 2013-07-03 | 2015-03-18 | Almirall, S.A. | New pyrazole derivatives as CRAC channel modulators |
| EP3033342A1 (en) * | 2013-08-13 | 2016-06-22 | Grünenthal GmbH | Annelated pyrroles and their use as crac inhibitors |
| WO2015086635A1 (en) | 2013-12-13 | 2015-06-18 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| CN105722834B (zh) | 2013-12-13 | 2017-12-22 | 豪夫迈·罗氏有限公司 | 酪氨酸蛋白激酶抑制剂 |
| CN106957252B (zh) * | 2014-11-19 | 2019-11-19 | 连云港恒运药业有限公司 | 一种质子泵抑制剂中间体及其制备方法 |
| LT3303330T (lt) | 2015-06-03 | 2019-08-12 | Bristol-Myers Squibb Company | 4-hidroksi-3-(heteroaril)piridin-2-ono apj agonistai, skirti panaudoti širdies ir kraujagyslių sutrikimų gydymui |
| TW201835036A (zh) | 2017-02-27 | 2018-10-01 | 瑞士商隆薩有限公司 | 製備1-甲基-3-(三氟甲基)-1h-吡唑-5-醇的方法 |
| US11548867B2 (en) | 2017-07-19 | 2023-01-10 | Idea Ya Biosciences, Inc. | Amido compounds as AhR modulators |
| US20210253593A1 (en) | 2017-11-14 | 2021-08-19 | Bristol-Myers Squibb Company | Substituted indole compounds |
| CA3085333A1 (en) | 2017-12-15 | 2019-06-20 | Bristol-Myers Squibb Company | Substituted indole ether compounds |
| BR112020011979A2 (pt) | 2017-12-19 | 2020-11-17 | Bristol-Myers Squibb Company | compostos de indol substituídos por amida úteis como inibidores de tlr |
| CN111699185B (zh) | 2017-12-19 | 2023-06-27 | 百时美施贵宝公司 | 6-氮杂吲哚化合物 |
| EA202091474A1 (ru) | 2017-12-19 | 2020-11-18 | Бристол-Маерс Сквибб Компани | Замещенные индольные соединения, применимые в качестве ингибиторов tlr |
| AU2018393003A1 (en) * | 2017-12-20 | 2020-08-06 | Bristol-Myers Squibb Company | Aryl and heteroaryl substituted indole compounds |
| CN111491929B (zh) | 2017-12-20 | 2023-11-28 | 百时美施贵宝公司 | 可用作tlr抑制剂的氨基吲哚化合物 |
| US11299501B2 (en) | 2017-12-20 | 2022-04-12 | Bristol-Myers Squibb Company | Diazaindole compounds |
| BR112021004893A2 (pt) | 2018-09-14 | 2021-06-01 | Rhizen Pharmaceuticals A G | composições compreendendo um inibidor de crac e um corticosteroide e métodos de uso dos mesmos |
| EP3628669A1 (en) * | 2018-09-28 | 2020-04-01 | GenKyoTex Suisse SA | Novel compounds as nadph oxidase inhibitors |
| EP3870583A1 (en) | 2018-10-24 | 2021-09-01 | Bristol-Myers Squibb Company | Substituted indole and indazole compounds |
| ES2963696T3 (es) | 2018-10-24 | 2024-04-01 | Bristol Myers Squibb Co | Compuestos diméricos de indol sustituidos |
| WO2020227484A1 (en) | 2019-05-09 | 2020-11-12 | Bristol-Myers Squibb Company | Substituted benzimidazolone compounds |
| CN115043770B (zh) * | 2022-07-21 | 2023-09-08 | 南京大学 | 一种吲哚/氮杂吲哚类化合物的光诱导合成方法 |
| CN115124410B (zh) * | 2022-08-13 | 2024-06-04 | 上海珂华生物科技有限公司 | 一种2-氟-4-羟基苯甲醛的制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5785055A (en) * | 1980-11-18 | 1982-05-27 | Konishiroku Photo Ind Co Ltd | Silver halide photographic recording material |
| JP2894617B2 (ja) * | 1989-12-16 | 1999-05-24 | 帝国臓器製薬株式会社 | ２―フエニルインドール誘導体 |
| FR2824827B1 (fr) * | 2001-05-17 | 2004-02-13 | Fournier Lab Sa | Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8 |
| US7008958B2 (en) * | 2002-05-21 | 2006-03-07 | Bristol-Myers Squibb Company | 2-substituted 5-oxazolyl indole compounds useful as IMPDH inhibitors and pharmaceutical compositions comprising same |
| PT1986633E (pt) * | 2006-02-10 | 2014-11-05 | Summit Corp Plc | Tratamento da distrofia muscular de duchenne |
| GB0602768D0 (en) * | 2006-02-10 | 2006-03-22 | Vastox Plc | Treatment of muscular dystrophy |
| US20090142832A1 (en) * | 2007-11-29 | 2009-06-04 | James Dalton | Indoles, Derivatives, and Analogs Thereof and Uses Therefor |
| US8785489B2 (en) * | 2008-10-17 | 2014-07-22 | Boehringer Ingelheim International Gmbh | Heteroaryl substituted indole compounds useful as MMP-13 inhibitors |
| KR20100092909A (ko) * | 2009-02-13 | 2010-08-23 | 주식회사 엘지생명과학 | 잔틴 옥시다제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물 |
| PE20120765A1 (es) * | 2009-03-27 | 2012-06-29 | Merck Sharp & Dohme | Inhibidores de la replicacion del virus de la hepatitis c |
-
2010
- 2010-09-21 KR KR1020127010486A patent/KR20120068947A/ko not_active Ceased
- 2010-09-21 RU RU2012116207/04A patent/RU2012116207A/ru not_active Application Discontinuation
- 2010-09-21 BR BR112012006630A patent/BR112012006630A2/pt not_active Application Discontinuation
- 2010-09-21 MX MX2012003539A patent/MX2012003539A/es not_active Application Discontinuation
- 2010-09-21 JP JP2012530236A patent/JP2013505913A/ja active Pending
- 2010-09-21 EP EP10754941A patent/EP2480529A1/en not_active Withdrawn
- 2010-09-21 WO PCT/EP2010/063838 patent/WO2011036130A1/en active Application Filing
- 2010-09-21 CA CA2771026A patent/CA2771026A1/en not_active Abandoned
- 2010-09-21 CN CN2010800426038A patent/CN102574788A/zh active Pending
- 2010-09-22 AR ARP100103446A patent/AR078408A1/es unknown
- 2010-09-23 TW TW099132213A patent/TW201121952A/zh unknown
- 2010-09-23 US US12/888,701 patent/US20110071150A1/en not_active Abandoned
-
2012
- 2012-08-15 JP JP2012180132A patent/JP2012246302A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013505913A (ja) | 2013-02-21 |
| CN102574788A (zh) | 2012-07-11 |
| MX2012003539A (es) | 2012-04-30 |
| EP2480529A1 (en) | 2012-08-01 |
| AR078408A1 (es) | 2011-11-02 |
| WO2011036130A1 (en) | 2011-03-31 |
| KR20120068947A (ko) | 2012-06-27 |
| US20110071150A1 (en) | 2011-03-24 |
| TW201121952A (en) | 2011-07-01 |
| JP2012246302A (ja) | 2012-12-13 |
| RU2012116207A (ru) | 2013-10-27 |
| CA2771026A1 (en) | 2011-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012006630A2 (pt) | derivados em indol como moduladores dos canais de cálcio ativados para liberação de cálcio (crac) | |
| ES2643164T3 (es) | Indol 7-sustituido como inhibidores de Mcl-1 | |
| BR112012004718A2 (pt) | compostos como moduladores de tirosina quinase | |
| BRPI0914942A2 (pt) | Compostos de oxindol | |
| DE112009004699A5 (de) | Elektrochirurgisches System | |
| BRPI0811639A2 (pt) | Cicloaquilaminas fenil substituídas como inibidores da recaptação de monoamina | |
| BR112013015260A2 (pt) | derivados de enxofre como moduladores de receptor de quimiocina | |
| PT2566327T (pt) | Indoles | |
| BRPI0918064A2 (pt) | distribuidor de substância | |
| BRPI0910585A2 (pt) | indóis como moduladores de receptor de aceticolina nicotínica do subtipo alfa-7 | |
| BRPI0819093A2 (pt) | compostos moduladores de sirtuína | |
| PT2382009E (pt) | Dispositivo de irradiação | |
| BRPI0922597A8 (pt) | ftalazinona e análogos relacionados como moduladores de sirtuína | |
| CU23870B1 (es) | Derivados de ciclopropilamida como moduladores h3 | |
| IL207684A0 (en) | Substituted indole derivatives | |
| BRPI0809221A2 (pt) | indol carboxamidas como inibidores de ikk2 | |
| BR112013013037A2 (pt) | derivados de indol como moduladores dos receptores de s1p | |
| BRPI1009200A2 (pt) | derivados de benzo tiadiazepinas como moduladores dos receptores ampa e nmda | |
| EP2421370A4 (en) | MGLUR5 RECEPTOR MODULATORS FILLED WITH 2-ALKYL PIPERIDINES | |
| BRPI0822058A2 (pt) | Derivados de 5-oxo-3-pirrolidinacarboxamida como moduladores de p2x7 | |
| BRPI0923005A2 (pt) | Metodos para modulacao dos exo de aves | |
| BRPI1008855A2 (pt) | derivados de indol como agentes anticâncer | |
| DK2515489T3 (da) | Forbedret multipleksering til enkelt RLC-enhed | |
| BR112013011865A2 (pt) | moduladores de gpr119 | |
| BRPI0806542A2 (pt) | Derivados de sulfonamida como inibidores de quimase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |